JP2009544610A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544610A5 JP2009544610A5 JP2009520782A JP2009520782A JP2009544610A5 JP 2009544610 A5 JP2009544610 A5 JP 2009544610A5 JP 2009520782 A JP2009520782 A JP 2009520782A JP 2009520782 A JP2009520782 A JP 2009520782A JP 2009544610 A5 JP2009544610 A5 JP 2009544610A5
- Authority
- JP
- Japan
- Prior art keywords
- immunization
- drug
- regulatory
- concomitant medication
- drug according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000003053 immunization Effects 0.000 claims 26
- 238000002649 immunization Methods 0.000 claims 26
- 229940124301 concurrent medication Drugs 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 239000002246 antineoplastic agent Substances 0.000 claims 7
- 210000003289 regulatory T cell Anatomy 0.000 claims 7
- 230000001235 sensitizing effect Effects 0.000 claims 7
- 229940000425 combination drug Drugs 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 230000006698 induction Effects 0.000 claims 5
- 230000003915 cell function Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- 229960001438 immunostimulant agent Drugs 0.000 claims 4
- 239000003022 immunostimulating agent Substances 0.000 claims 4
- 230000003308 immunostimulating effect Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000003796 beauty Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 229940044683 chemotherapy drug Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 210000004324 lymphatic system Anatomy 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108020000411 Toll-like receptor Proteins 0.000 claims 1
- 102000002689 Toll-like receptor Human genes 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011277 treatment modality Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Claims (25)
- 化学療法薬およびＣＴＬ誘導併用薬を含む免疫感作併用薬であって、
該化学療法薬は、患者中の腫瘍と接触して、腫瘍の炎症の促進および制御性Ｔ細胞機能の干渉の少なくとも１つを達成し、
該ＣＴＬ誘導併用薬は、第１の抗原に特異的なＣＴＬ応答を誘導し、
該ＣＴＬ誘導併用薬は、該第１の抗原の少なくとも一部もしくはその免疫原性フラグメントおよび免疫賦活薬を含むかまたはコードする免疫原を含む、該患者に送達するための第１の組成物、及び、該第１の抗原のエピトープに対応するペプチドを含む、該患者のリンパ系に直接投与するための第２の組成物を含み、
該併用により、該化学療法剤または該ＣＴＬ誘導併用薬のみのいずれかの有効性よりも治療有効性が増強される、免疫感作併用薬。 - 前記第１の組成物及び第２の組成物が同一ではない、請求項１に記載の免疫感作併用薬。
- 前記第１の組成物が第１の抗原又はその免疫原性フラグメントをコードする核酸を含む、請求項１に記載の免疫感作併用薬。
- 前記第１の組成物が免疫原性ポリペプチド及び免疫賦活薬を含む、請求項１に記載の免疫感作併用薬。
- 前記免疫賦活薬がサイトカインである、請求項１〜４のいずれか１項に記載の免疫感作併用薬。
- 前記免疫賦活薬がトール様受容体リガンドである、請求項１〜４のいずれか１項に記載の免疫感作併用薬。
- 前記送達が前記患者のリンパ系への直接投与を含む、請求項１〜６のいずれか１項に記載の免疫感作併用薬。
- 前記送達又は投与が単回ボーラス注射を含む、請求項１〜７のいずれか１項に記載の免疫感作併用薬。
- 前記送達又は投与が反復ボーラス注射を含む、請求項１〜７のいずれか１項に記載の免疫感作併用薬。
- 前記化学療法薬が制御性Ｔ細胞活性を下方制御するか又は枯渇させ、それにより、腫瘍細胞又は癌細胞内のエフェクターＴ細胞活性を促進するか又は増強する、請求項１〜９のいずれか１項に記載の免疫感作併用薬。
- 前記制御性Ｔ細胞機能の干渉が制御性Ｔ細胞数の減少を含む、請求項１〜１０のいずれか１項に記載の免疫感作併用薬。
- 前記制御性Ｔ細胞機能の干渉が制御性Ｔ細胞活性の低下を含む、請求項１〜１０のいずれか１項に記載の免疫感作併用薬。
- 前記化学療法薬がシクロホスファミド、ゲムシタビン、フルダラビン、及びドキソルビシンから成る群から選択される、請求項１〜１２のいずれか１項に記載の免疫感作併用薬。
- 前記化学療法薬がシクロホスファミドである、請求項１３に記載の免疫感作併用薬。
- 前記接触が、制御性Ｔ細胞機能の惹起、異常な細胞増殖の誘導、又は腫瘍成長が認められた際に行われる、請求項１〜１４のいずれか１項に記載の免疫感作併用薬。
- 前記接触及び誘導が２回以上のサイクルで繰り返される、請求項１〜１５のいずれか１項に記載の免疫感作併用薬。
- 前記接触及び誘導が、制御性Ｔ細胞活性の減少又は異常な細胞増幅若しくは腫瘍成長の抑制が達成されるまで繰り返される、請求項１６に記載の免疫感作併用薬。
- 前記接触が前記誘導の前に行われる、請求項１〜１５のいずれか１項に記載の免疫感作併用薬。
- 前記接触が前記誘導の前に繰り返される、請求項１８に記載の免疫感作併用薬。
- 前記接触が前記誘導の６、７、８、又は９日前に完了する、請求項１８または１９に記載の免疫感作併用薬。
- 前記接触が前記投与の前に繰り返される、請求項１〜２０のいずれか１項に記載の免疫感作併用薬。
- 前記送達及び前記投与が少なくとも約２、３、４、５、６、又は７日間あけて行われる、請求項１〜２１のいずれか１項に記載の免疫感作併用薬。
- 前記送達が前記接触の後に行われる、請求項１〜１５のいずれか１項に記載の免疫感作併用薬。
- 前記送達が化学療法薬の投与前又は投与後に抗原のエピトープに対応する１つ又は複数のペプチドを投与することを含む、請求項１〜２３のいずれか１項に記載の免疫感作併用薬。
- 前記接触の前又は接触の間に、放射線療法、遺伝子療法、生化学療法、及び手術から成る群から選択される少なくとも１つの治療様式がさらに行われる、請求項１〜２４のいずれ
か１項に記載の免疫感作併用薬。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83125606P | 2006-07-14 | 2006-07-14 | |
| US86333206P | 2006-10-27 | 2006-10-27 | |
| PCT/US2007/016075 WO2008008541A2 (en) | 2006-07-14 | 2007-07-14 | Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes |
| US11/879,078 US20080014211A1 (en) | 2006-07-14 | 2007-07-14 | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic and therapeutic purposes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009544610A JP2009544610A (ja) | 2009-12-17 |
| JP2009544610A5 true JP2009544610A5 (ja) | 2010-09-02 |
Family
ID=38922728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009520782A Withdrawn JP2009544610A (ja) | 2006-07-14 | 2007-07-14 | 予防又は治療目的のためにｍｈｃクラスｉ拘束エピトープに対する免疫応答を引き出し、増強し、保持する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080014211A1 (ja) |
| EP (1) | EP2046344A2 (ja) |
| JP (1) | JP2009544610A (ja) |
| AU (1) | AU2007272785A1 (ja) |
| CA (1) | CA2657771A1 (ja) |
| MX (1) | MX2009000452A (ja) |
| WO (1) | WO2008008541A2 (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| WO2006071990A2 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to bypass cd+4 cells in the induction of an immune response |
| WO2006138568A2 (en) * | 2005-06-17 | 2006-12-28 | Mannkind Corporation | Multivalent entrain-and-amplify immunotherapeutics for carcinoma |
| EP2385060A3 (en) | 2005-06-17 | 2012-02-15 | Mannkind Corporation | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| US9486524B2 (en) * | 2006-09-01 | 2016-11-08 | Genticel | Composition for eliciting a specific CTL response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells |
| US20110274723A1 (en) * | 2009-10-23 | 2011-11-10 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
| WO2012145671A1 (en) * | 2011-04-20 | 2012-10-26 | The Trustees Of The University Of Pennsylvania | Radioisotope-photodynamic therapy for cancer treatment |
| US10578619B2 (en) * | 2013-07-31 | 2020-03-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits for identifying effector Treg cells |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037135A (en) * | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| US5747271A (en) * | 1992-12-22 | 1998-05-05 | Ludwig Institute For Cancer Research | Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals |
| US5698396A (en) * | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| US6994851B1 (en) * | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
| US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| US20030138808A1 (en) * | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
| US6709844B1 (en) * | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
| US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
| NZ521715A (en) * | 2000-04-28 | 2008-01-31 | Mannkind Corp | Method of identifying and producing antigen peptides and use thereof as vaccines |
| US6861234B1 (en) * | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
| EP1301551A2 (en) * | 2000-07-14 | 2003-04-16 | Metabolix, Inc. | Polyurethanes obtained from hydroxyalkanoates and isocyanates |
| AU2002247304A1 (en) * | 2001-03-07 | 2002-09-19 | Mannkind Corporation | Anti-neovasculature preparations for cancer |
| WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| CN1313617C (zh) * | 2001-11-07 | 2007-05-02 | 曼康公司 | 编码靶相关抗原表位的表达载体及其设计方法 |
| JP2005537800A (ja) * | 2002-09-06 | 2005-12-15 | マンカインド コーポレイション | エピトープ配列 |
| GB0221574D0 (en) * | 2002-09-17 | 2002-10-23 | Isis Innovation | Treatments |
| CN104147597A (zh) * | 2002-12-16 | 2014-11-19 | 全球免疫股份有限公司 | 用于免疫治疗的基于酵母的疫苗 |
| MXPA05013973A (es) * | 2003-06-17 | 2006-03-02 | Mannkind Corp | Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos. |
| WO2004112825A2 (en) * | 2003-06-17 | 2004-12-29 | Mannkind Corporation | Combinations of tumor-associated antigens for the treatment of various types of cancers |
| JP2008503494A (ja) * | 2004-06-17 | 2008-02-07 | マンカインド コーポレイション | 診断方法を治療方法と統合することによる免疫療法の効力改善 |
| US20060008468A1 (en) * | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| US20060159689A1 (en) * | 2004-06-17 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| AU2005265182B2 (en) * | 2004-06-17 | 2012-06-21 | Mannkind Corporation | Epitope analogs |
| WO2006071934A2 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
| WO2006071990A2 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to bypass cd+4 cells in the induction of an immune response |
| US20060159694A1 (en) * | 2004-12-29 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in compositions for various types of cancers |
| EP1835932A2 (en) * | 2004-12-29 | 2007-09-26 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
| EP2371851A3 (en) * | 2005-06-17 | 2012-08-01 | Mannkind Corporation | Epitope analogues |
| WO2006138568A2 (en) * | 2005-06-17 | 2006-12-28 | Mannkind Corporation | Multivalent entrain-and-amplify immunotherapeutics for carcinoma |
| EP2385060A3 (en) * | 2005-06-17 | 2012-02-15 | Mannkind Corporation | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| GB0519303D0 (en) * | 2005-09-21 | 2005-11-02 | Oxford Biomedica Ltd | Chemo-immunotherapy method |
-
2007
- 2007-07-14 WO PCT/US2007/016075 patent/WO2008008541A2/en active Application Filing
- 2007-07-14 MX MX2009000452A patent/MX2009000452A/es not_active Application Discontinuation
- 2007-07-14 EP EP07810479A patent/EP2046344A2/en not_active Withdrawn
- 2007-07-14 US US11/879,078 patent/US20080014211A1/en not_active Abandoned
- 2007-07-14 JP JP2009520782A patent/JP2009544610A/ja not_active Withdrawn
- 2007-07-14 AU AU2007272785A patent/AU2007272785A1/en not_active Abandoned
- 2007-07-16 CA CA002657771A patent/CA2657771A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544610A5 (ja) | ||
| Frega et al. | Trial Watch: experimental TLR7/TLR8 agonists for oncological indications | |
| Gatti-Mays et al. | Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations | |
| Wang et al. | BNCT for locally recurrent head and neck cancer: preliminary clinical experience from a phase I/II trial at Tsing Hua open-pool reactor | |
| Garbe et al. | Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting | |
| JP2013536157A5 (ja) | ||
| JP2010529026A5 (ja) | ||
| Confino et al. | Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alpha-irradiation combined with inhibitors of immunosuppression and CpG | |
| JP2006506441A5 (ja) | ||
| Gunderson et al. | Exploring optimal sequencing of radiation and immunotherapy combinations | |
| JP2012102122A5 (ja) | ||
| Domankevich et al. | RIG-1-like receptor activation synergizes with intratumoral alpha radiation to induce pancreatic tumor rejection, triple-negative breast metastases clearance, and antitumor immune memory in mice | |
| Soukup et al. | Radiation meets immunotherapy–a perfect match in the era of combination therapy? | |
| Kubicek et al. | Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies | |
| Weintraub et al. | Advances in intravesical therapy for the treatment of non‑muscle invasive bladder cancer | |
| JP2019531293A5 (ja) | ||
| JP2016526531A5 (ja) | ||
| Nadella et al. | Emerging neo adjuvants for harnessing therapeutic potential of M1 tumor associated macrophages (TAM) against solid tumors: Enusage of plasticity | |
| JP2018100243A5 (ja) | ||
| Wu et al. | Intraperitoneal administration of poly (I: C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors | |
| Holay et al. | Single low-dose nanovaccine for long-term protection against anthrax toxins | |
| CN110996991A (zh) | haNK西妥昔单抗组合和方法 | |
| Tiwari et al. | Immunotherapy: Advancing glioblastoma treatment—A narrative review of scientific studies | |
| Oratz et al. | Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma | |
| TWI705972B (zh) | 惡性病變的組合治療 |